Stroke

Neurology·MeSH: Stroke

Prevalence

1358.1 / 100K

Incidence

171.6 / 100K/yr

67 drugs in development·39 companies·60 clinical trials

Drug Pipeline by Phase

Approved(23)

Drug	Company
amlodipine	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)
apixaban	Impax Laboratories, LLC (IPXL)
apixaban	Mylan II B.V. (MYL)
candesartan cilexetil	Aptinyx Inc. (APTX)
clopidogrel bi	Teva Pharmaceutical Industries Limited (TEVA)
clopidogrel bi	DR REDDYS LABORATORIES LTD (RDY)
exforge hct	Novartis AG (NVS)
felodipine	Mylan II B.V. (MYL)
losartan	Teva Pharmaceutical Industries Limited (TEVA)
losartan	Mylan II B.V. (MYL)
nebivolol	ANI PHARMACEUTICALS INC (ANIP)
NEUROLITE	Lantheus Holdings, Inc. (LNTH)
olmesartan medoxomil	Amneal Pharmaceuticals, Inc. (AMRX)
ozempic	Novo Nordisk A/S (NVO)
pravastatin	Aptinyx Inc. (APTX)
spironolactone	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)
telmisartan	Inventiva S.A. (IVA)
ticagrelor	Mylan II B.V. (MYL)
ticagrelor	Amneal Pharmaceuticals, Inc. (AMRX)
ticagrelor	DR REDDYS LABORATORIES LTD (RDY)
valsartan	Mylan II B.V. (MYL)
VASCEPA (VAZKEPA in EU)	AMARIN CORP PLCUK (AMRN)
VASCEPA (VAZKEPA)	AMARIN CORP PLCUK (AMRN)

Phase 3(8)

Drug	Company
cytoflavin	NYMOX PHARMACEUTICAL CORP (NYMXF)
cytoflavin	NYMOX PHARMACEUTICAL CORP (NYMXF)
milvexian	GH Research PLC (GHRS)
Milvexian	BRISTOL MYERS SQUIBB CO (BMY)
NT 201	Revance Therapeutics, Inc. (RVNC)
tak-755	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-755	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
Tenecteplase	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 2(16)

Drug	Company
Acetylcysteine	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Acetylcysteine	Structure Therapeutics Inc. (GPCR)
Acetylcysteine	Cidara Therapeutics, Inc. (CDTX)
Acetylcysteine	Filana Therapeutics Inc. (FLNA)
Acetylcysteine	PROTHENA CORP PUBLIC LTD CO (PRTA)
Albumin infusion	Cidara Therapeutics, Inc. (CDTX)
Capsaicin Transmucosal Oral Film	Valneva SE (VALN)
cenplacel-l	Celularity Inc. (CELU)
Dextrose in Water	Structure Therapeutics Inc. (GPCR)
Dextrose in Water	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Dextrose in Water	Cidara Therapeutics, Inc. (CDTX)
Dextrose in Water	Filana Therapeutics Inc. (FLNA)
Dextrose in Water	PROTHENA CORP PUBLIC LTD CO (PRTA)
MSC	Accustem Sciences Inc. (ACUT)
TAK-755	Merus N.V. (MRUS)
Tenecteplase	Valneva SE (VALN)

Phase 1(3)

Drug	Company
hutrukin	XBiotech Inc. (XBIT)
mycophenolate acid	Cidara Therapeutics, Inc. (CDTX)
Peripheral Blood Stem Cell Infusion	Cidara Therapeutics, Inc. (CDTX)

Preclinical(9)

Drug	Company
anti-il-1a	XBiotech Inc. (XBIT)
ANVS405	Annovis Bio, Inc. (ANVS)
BXT-25	BIOXYTRAN, INC (BIXT)
electroceuticals therapeutic devices	ENDONOVO THERAPEUTICS, INC. (ENDV)
ht-tbi	Hoth Therapeutics, Inc. (HOTH)
neurohub	BRAIN SCIENTIFIC INC. (BRSF)
phorbol esters	HYPGEN INC (HPGN)
rp-323	RICH PHARMACEUTICALS, INC. (RCHA)
sequential-dialysis technique	PREMIER BIOMEDICAL INC (BIEI)

Unknown(1)

Drug	Company
single antiplatelet therapy or no therapy	BRAIN SCIENTIFIC INC. (BRSF)

Phase 2/Phase 3(1)

Drug	Company
Recombinant human tissue kallikrein	DiaMedica Therapeutics Inc. (DMAC)

Phase 4(6)

Drug	Company
Acetylsalicylic acid	Cidara Therapeutics, Inc. (CDTX)
Botulinum toxin injection	Revance Therapeutics, Inc. (RVNC)
Lidocaine Infusion	Cidara Therapeutics, Inc. (CDTX)
Nefopam 120mg/day infusion	Cidara Therapeutics, Inc. (CDTX)
Tirofiban	Cidara Therapeutics, Inc. (CDTX)
Tirofiban	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 67 drugs in development for Stroke across 39 companies.

There are 60 clinical trials targeting Stroke tracked by BioSniper.

The estimated prevalence of Stroke is approximately 1358.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.